Other HER-2-directed therapies, such as the antibody drug conjugate (trastuzumab-emtansine, TDM-1), have demonstrated promising results in preclinical studies [29] and clinical trials in CCA are planned. This evidence concerns the gene ERBB2 and cholangiocarcinoma.